Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

S0150000

Sulfate de salbutamol

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Salbutamol hemisulfate salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C13H21NO3 · 0.5H2SO4
Numéro CAS:
51022-70-9
Poids moléculaire :
288.35
Numéro MDL:
MFCD00055200
Code UNSPSC :
41116107
ID de substance PubChem :
329824415
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

albuterol, salbutamol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

Clé InChI

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Informations sur le gène

human ... ADRB2(154)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Salbutamol sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000034

Salbutamol impurity G, European Pharmacopoeia (EP) Reference Standard

Y0000030

Salbutamol impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000031

Salbutamol impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000071

Salbutamol impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000032

Salbutamol impurity I, European Pharmacopoeia (EP) Reference Standard

S0100000

Salbutamol, European Pharmacopoeia (EP) Reference Standard

Y0001186

Salbutamol impurity J, European Pharmacopoeia (EP) Reference Standard

Y0001288

Salbutamol hemisulfate salt, European Pharmacopoeia (EP) Reference Standard

1012633

Sulfate d'albutérol, United States Pharmacopeia (USP) Reference Standard

1358784

Levalbuterol hydrochloride, United States Pharmacopeia (USP) Reference Standard

1012600

Salbutamol, United States Pharmacopeia (USP) Reference Standard

1012644

Albuterol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1012655

Albuterol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1012689

Albuterol Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP451

Salbutamol, British Pharmacopoeia (BP) Reference Standard

BP302

Sulfate de salbutamol, British Pharmacopoeia (BP) Reference Standard

PHR1960

Salbutamol Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2040

Albuterol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1961

Salbutamol Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1962

Salbutamol impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

BP712

Salbutamol aldehyde impurity, British Pharmacopoeia (BP) Reference Standard

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate, British Pharmacopoeia (BP) Reference Standard

BP852

Salbutamol impurity B, British Pharmacopoeia (BP) Reference Standard

BP704

Salbutamol ketone impurity, British Pharmacopoeia (BP) Reference Standard

PHR2106

4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-methylphenol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9050

4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9071

4-[2-[Benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

1012564

Albuterol Related Compound I, United States Pharmacopeia (USP) Reference Standard

PHR2332

Methyl5-[2-[benzyl(tert-butyl)amino]acetyl]-2-hydroxybenzoate hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H317,H351,H361fd

Classification des risques

Carc. 2 - Repr. 2 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

B Padhukasahasram et al.
The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was
Marc L Decramer et al.
International journal of chronic obstructive pulmonary disease, 8, 53-64 (2013-02-05)
Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence
Lawrence M Lewis et al.
Chest, 145(1), 53-59 (2013-08-21)
Controversy exists around the incidence and cause of hyperlactatemia during asthma exacerbations. We evaluated the incidence, potential causes, and adverse events of hyperlactatemia in patients with acute asthma exacerbation. This study was a subanalysis of subjects receiving placebo from a
Abebaw M Yohannes et al.
International journal of chronic obstructive pulmonary disease, 8, 117-125 (2013-03-22)
Tiotropium bromide is an anticholinergic agent that has gained worldwide acceptance as a first-line, once daily maintenance therapy for patients with moderate-to-severe chronic obstructive pulmonary disease. The purpose of this review is to synthesize the evidence base in the past
Helgo Magnussen et al.
The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)
Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique